Dataset Open Access

Generation of stable mammalian cell lines for the expression of proteins related to COVID-19 through random integration

Wong, Jong Fu; Coker, Jesse; Fernandez-Cid, Alejandra; Mukhopadhyay, Shubhashish; Bohstedt, Tina; A Burgess-Brown, Nicola; Bullock, Alex

DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="" xmlns="" xsi:schemaLocation="">
  <identifier identifierType="DOI">10.5281/zenodo.3958921</identifier>
      <creatorName>Wong, Jong Fu</creatorName>
      <givenName>Jong Fu</givenName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="">0000-0001-6539-5865</nameIdentifier>
      <affiliation>Structural Genomics Consortium</affiliation>
      <creatorName>Coker, Jesse</creatorName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="">0000-0003-1842-9860</nameIdentifier>
      <affiliation>Structural Genomics Consortium</affiliation>
      <creatorName>Fernandez-Cid, Alejandra</creatorName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="">0000-0002-6746-6791</nameIdentifier>
      <affiliation>Structural Genomics Consortium</affiliation>
      <creatorName>Mukhopadhyay, Shubhashish</creatorName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="">0000-0003-1430-5529</nameIdentifier>
      <affiliation>Structural Genomics Consortium</affiliation>
      <creatorName>Bohstedt, Tina</creatorName>
      <affiliation>Structural Genomics Consortium</affiliation>
      <creatorName>A Burgess-Brown, Nicola</creatorName>
      <familyName>A Burgess-Brown</familyName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="">0000-0003-0463-445X</nameIdentifier>
      <affiliation>Structural Genomics Consortium</affiliation>
      <creatorName>Bullock, Alex</creatorName>
      <affiliation>Structural Genomics Consortium</affiliation>
    <title>Generation of stable mammalian cell lines for the expression of proteins related to COVID-19 through random integration</title>
    <subject>stable cell</subject>
    <subject>protein expression</subject>
    <subject>random integration</subject>
    <date dateType="Issued">2020-07-24</date>
  <resourceType resourceTypeGeneral="Dataset"/>
    <alternateIdentifier alternateIdentifierType="url"></alternateIdentifier>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsVersionOf">10.5281/zenodo.3958920</relatedIdentifier>
    <relatedIdentifier relatedIdentifierType="URL" relationType="IsPartOf"></relatedIdentifier>
    <relatedIdentifier relatedIdentifierType="URL" relationType="IsPartOf"></relatedIdentifier>
    <rights rightsURI="">Creative Commons Attribution 4.0 International</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
    <description descriptionType="Abstract">&lt;p&gt;Scientists centred around University of Oxford came together in the current COVID-19 pandemic to contribute to relevant studies collaboratively. Researchers with no prior experience in virology studies, myself included, had volunteered our time to contribute whichever way we can based on our field of expertise. The Biotech team of SGC Oxford, headed by Nicola Burgess-Brown had taken up the role of producing proteins used in serological assays, basic research to understand COVID-19 pathophysiology and hunt for treatment compounds. The initial production of these proteins was based on transient transfection of expression construct DNA into mammalian cells. This approach was laborious and consumed large amounts of plasmid DNA. Therefore, I volunteered to generate stable expression cell lines that will negate the constant need for transfection.&lt;/p&gt;

&lt;p&gt;I aimed to stably integrate the expression constructs into the genome of Expi293F human cells commonly used in large scale protein production. The expression constructs carried neomycin marker for selection in mammalian cells. Toxicity to the cells is not a concern in this case because the expressed proteins are secreted into the medium and do not build up in the cells. The expression constructs are randomly integrated into the genome mainly via non-homologous end-joining (NHEJ). An advantage of this approach is that molecular sub-cloning is not necessary.&lt;/p&gt;

&lt;p&gt;In order to maximise the rate of correct integration of the expression constructs, restriction digestion was performed to cut once between the expression cassette and antibiotic resistance cassette (refer to cartoon in Figure 1). Without this step, the construct DNA will be broken at a random position during the integration step, potentially disrupting the expression cassette. I have also tested the effect of actively creating double strand breaks (DSBs) in the genome of the cells on the integration efficiency. More DSBs in the genome might increase the incidence of NHEJ and integration of our constructs. This was achieved by co-transfection of AAVS1 CRISPR/eSpCas9(1.1) construct (refer to cartoon in Figure 1). The eSpCas9(1.1)_No_FLAG_AAVS1_T2 construct was a gift from Yannick Doyon (Addgene plasmid # 79888 ; ; RRID:Addgene_79888)&lt;/p&gt;


&lt;p&gt;Please refer to my SGC opennotebook post for my other research work unrelated to the pandemic.&lt;/p&gt;

All versions This version
Views 193193
Downloads 100100
Data volume 42.3 MB42.3 MB
Unique views 161161
Unique downloads 8686


Cite as